Management Comment “This agreement with Takara Bio will not only secure the manufacturing of Cellectis’ robust product pipeline but also strengthen our key assets and capabilities in the cell engineering space” said Dr David Sourdive, EVP Corporate Development at Cellectis. “The partnership ultimately furthers our effort to provide universal CAR-Ts for immunotherapy patients all over the world.”